- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07736885
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.
Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.
Who can participate: Adults aged [35-80] who have had an ischemic stroke and now have mild to moderate cognitive impairment.
What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.
Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.
Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Liang Gao
- Numéro de téléphone: 8618722216295
- E-mail: Gaoliang202605@163.com
Lieux d'étude
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300073
- Recrutement
- The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
-
Contact:
- Liang Gao
- Numéro de téléphone: 8618722216295
- E-mail: Gaoliang202605@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Aged 35-80 years;
- Stroke duration within 2 weeks to 6 months post-onset;
- Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26;
- Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);
- No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;
- Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.
Exclusion Criteria:
- Unstable vital signs or life-threatening comorbidities;
- Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.);
- History of epilepsy or epileptic seizures;
- Pregnant or lactating women;
- Concurrent use of other medications affecting cognitive function;
- Allergy to the study intervention device or history of serious adverse reactions;
- Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);
- Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Active TES Group
Participants receive transcutaneous electrical stimulation at hand Jing-Well acupoints (Shaoze SI1, Shangyang LI1, Zhongchong PC9, Guanchong SJ1, Shaochong HT9, and Dadun LR1) using a portable stimulator.
Stimulation parameters: 10 Hz square wave, pulse width 320 μs, intensity adjusted to individual tolerance (typically 0-1 mA), 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
Stimulation parameters: square wave, frequency 10 Hz, pulse width 320 μs, intensity individually titrated to sensory threshold (typically 0-1 mA), session duration 30 minutes.
Treatment schedule: 6 sessions per week (Monday-Saturday) for 4 consecutive weeks, totaling 24 sessions.
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
|
Comparateur factice: Sham TES Group
Participants receive sham transcutaneous electrical stimulation at hand Jing-Well acupoint locations using an identical-appearing device with the same electrode placement pattern as the active group.
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based sham transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator with open-circuit design (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
MoCA(Montreal Cognitive Assessment)
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Mini-Mental State Examination(MMSE)
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Vascular Dementia Assessment Scale-cognitive subscale(VaDAS-cog )
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Activities of Daily Living Scale(ADL)
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Whole-brain frequency band absolute and relative power derived from resting-state electroencephalography (EEG)
Délai: From enrollment to the end of treatment at 4 weeks
|
Resting-state EEG signals will be acquired.
Absolute power and relative power of multiple frequency bands (delta, theta, alpha, beta) across the whole brain will be quantified to reflect cortical electrical activity.
|
From enrollment to the end of treatment at 4 weeks
|
|
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) measured by functional near-infrared spectroscopy (fNIRS)
Délai: From enrollment to the end of treatment at 4 weeks
|
Prefrontal cortical hemodynamic signals will be acquired via resting-state functional near-infrared spectroscopy.
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) will be quantified to evaluate cerebral hemodynamic function.
|
From enrollment to the end of treatment at 4 weeks
|
|
C-Reactive Protein
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Folic Acid / Folate
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Homocysteine(Hcy)
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Vitamin B12 / Cobalamin
Délai: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009 Jun;40(6):2276-93. doi: 10.1161/STROKEAHA.108.192218. Epub 2009 May 7.
- Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jul;44(7):2064-89. doi: 10.1161/STR.0b013e318296aeca. Epub 2013 May 7.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Les troubles mentaux
- Troubles neurocognitifs
- Troubles cognitifs
- Accident vasculaire cérébral
- AVC ischémique
- AVC hémorragique
- Dysfonctionnement cognitif
Autres numéros d'identification d'étude
- TYLL2026-K-076
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .